|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
Biomarker
|
disease |
BEFREE |
A recent phase I first-in-human study of the BCL-2 inhibitor venetoclax in non-Hodgkin lymphoma showed an overall response rate of 44%.
|
29666304 |
2018 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Antisense oligodeoxyribonucleotide down-regulation of bcl-2 gene expression inhibits growth of the low-grade non-Hodgkin's lymphoma cell line WSU-FSCCL.
|
8528964 |
1995 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Twenty-nine cases of non-Hodgkin's lymphoma of low-grade malignancy in a European population were investigated for the presence of bcl-2 and bcl-1 gene rearrangement.
|
1757070 |
1991 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Clinical significance of bcl-2-MBR gene rearrangement and protein expression in diffuse large-cell non-Hodgkin's lymphoma: an analysis of 83 cases.
|
8270971 |
1994 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study was planned with the aim to investigate the association between bcl-2 gene rearrangements and apoptotic changes during chemotherapy in patients with non-Hodgkin's lymphoma.
|
10074891 |
1999 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
Biomarker
|
disease |
BEFREE |
The first member of this gene family to be identified was BCL-2, by virtue of its involvement in t(14;18) chromosomal translocations commonly found in B-cell non-Hodgkin's lymphoma (NHL).
|
9408956 |
1997 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Some evidence suggests that IL-10 might be associated with the progression of T-cell NHLs and that IL-10 may be involved in a rescue effect, protecting T cells from apoptotic cell death associated with upregulated bcl-2 expression.
|
17408400 |
2007 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide.
|
10873104 |
2000 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Ongoing clinical trials are exploring the role of Bcl-2 downregulation with oblimersen (Bcl-2 antisense) in patients with non-Hodgkin's lymphoma, chronic lymphocytic leukemia and multiple myeloma.
|
15784299 |
2005 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
Biomarker
|
disease |
CTD_human |
Copper-64-labeled anti-bcl-2 PNA-peptide conjugates selectively localize to bcl-2-positive tumors in mouse models of B-cell lymphoma.
|
26239085 |
2015 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Incidence of BCL-2 gene rearrangements in Argentinean non-Hodgkin lymphoma patients: increased frequency of breakpoints outside of MBR and MCR.
|
14757440 |
2004 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
Biomarker
|
disease |
BEFREE |
The cumulative poor effect of both p53 and bcl-2 in large B-cell lymphomas, which is more significant in nodal tumours, could confirm the existence of a multistep genetic deregulation in non-Hodgkin's lymphoma.
|
8297731 |
1994 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
Biomarker
|
disease |
BEFREE |
We conclude that bcl-2 gene deregulation, but not the precise moment at which this occurs during the pre-B-cell stage, influences the development of follicular NHL.
|
8555066 |
1995 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
DNA was extracted from archival CPs of B-cell NHL cases with previous fluorescence in situ hybridization (FISH) assays for MYC rearrangement and/or IGH/BCL-2 translocation.
|
25807917 |
2015 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
High levels of BACH2 associated with lower levels of BCL2 transcript abundance in t(14;18)(q21;q34) translocation positive non-Hodgkin's lymphoma.
|
18929412 |
2009 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Other studies have suggested an inverse relationship between p53 and bcl-2 protein expression in breast and colonic cancers and in a variety of subtypes of non-Hodgkin's lymphoma.
|
9349233 |
1997 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Targeting the proapoptotic factor Bcl-2 in non-Hodgkin's lymphoma.
|
15651174 |
2004 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Multiplex PCR for the detection of BCL-1/IGH and BCL-2/IGH gene rearrangements--clinical validation in a prospective study of blood and bone marrow in 258 patients with or suspected of non-Hodgkin's lymphoma.
|
17438702 |
2007 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Prognostic significance of CD95, P53, and BCL2 expression in extranodal non-Hodgkin's lymphoma.
|
20352431 |
2010 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, two other genes, BCL6 and BCL2, which are classically related to apoptosis and non-Hodgkin lymphoma, were shown for the first time to be involved in amplification.
|
15611930 |
2005 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
p53 mutations, c-myc and bcl-2 rearrangements in human non-Hodgkin's lymphoma cell lines.
|
8574164 |
1995 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interestingly these fragile sites were located in the same chromosomal bands as the oncogenes, MOS, MYC, BCL-1 and BCL-2 as well as cancer breakpoints specifically associated with non-Hodgkin's lymphoma, suggesting the possibility that fragile sites may play a critical role in the pathogenesis of non-Hodgkin's lymphoma.
|
7954347 |
1994 |